Promising New Neoadjuvant Strategy in Luminal B Breast Cancer Promising New Neoadjuvant Strategy in Luminal B Breast Cancer
The combination of ribociclib and letrozole proved to a viable alternative to standard multidrug neoadjuvant chemotherapy for women with high-risk luminal B breast cancer in an exploratory phase 2 trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Women